RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Consequences of a "no" vote: from IR Well, poof, the share price hit 3¢ yesterday, the lowest in it's history. The markets haven't thought very much of Midatech and Bioasis for a long time and they have absolutely killed the share price since December 13.
I think investors are saying that they don't detect much value coming their way and a lot of value going to LT and The Placee, and for Bioasis shareholders, there is no evidence that the major xB3 IP, including the platform and xB3-001, 004, etc., will be retained by Biodexa.
The major xB3 IP disappeared when it should have been promoted to the benefit of Bioasis shareholders. It was no accident that the IP was "shelved," a word used by Rathjen. That was by choice. How do you lose 40 pages from a corporate presentation, pages that had the good stuff on them?
I predicted ten years ago that if Bioasis did not move to the clinic that the company would not have control over its own story or future. I stated the possibility out loud four years ago that Bioasis was being positioned for a selloff. I said that out loud!
So far, my "conspiracy theories" have come true. Shareholders have been beaten. The question is what combination of incompetence, greed and malice caused the 15-year failure.
So how does malice manifest itself? How is it accomplished in a legal manner under the watchful eyes of regulators and the market? It's done exactly like this. You're protecting the alpha dogs and narcissists, poof. As a trader who pumps his current trade, I suspect you identify more closely with them than you do with shareholders.
My "conspiracy theories" have been placed into the record so that when you later determine who is making the big bucks from xB3, you will recognize it and how it came about.
I don't really believe that Biodexa is the endplay for the players. That's why Biodexa gets EGF, Hunter Syndrome, some minor xB3 payloads, licenses for its own technologies and maybe some deals with existing Bioasis partners. It's all good and it might create value, but I don't see the platform and the "shelved" drugs, the really high value ones, staying with Biodexa. They could, but I can't quite believe.
It will likely be very few months before it's known whether I'm a conspiracy theorist or whether I know how these things can be positioned and then accomplished.
jd